Executive Interview – Adherium

Executive Interview – Adherium

Adherium (ADR.ASX) is an ASX-listed digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Adherium’s market-leading Smartinhaler platform has been independently proven to improve adherence to inhaled medications and improve health outcomes in chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). With an existing 10-year commercial product development and supply agreement with AstraZeneca (AZN) and strong relationships with other global pharmaceutical and medical technology companies and key opinion leaders (KOLs) through sales into the clinical trial sector, Adherium is positioned for strong revenue growth. The company listed on the ASX in August 2015, raising A$35m at A$0.50/share, including a US$3m investment by AZN.


You may also be interested in these:

Screenshot 2024-07-01 133526

Real Estate

Regional REIT - executive interview

Industrials

Electro Optic Systems – Brand video

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free